PMab-235: A monoclonal antibody for immunohistochemical analysis against goat podoplanin.

Goat podoplanin Lymphatic endothelial cells PDPN PMab-235

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 18 02 2019
revised: 10 05 2019
accepted: 05 07 2019
entrez: 25 7 2019
pubmed: 25 7 2019
medline: 25 7 2019
Statut: epublish

Résumé

Sensitive and specific monoclonal antibodies (mAbs) against not only human but also mouse, rat, rabbit, dog, cat, bovine, pig, and horse podoplanins (PDPNs) have been established in our previous studies. However, anti-goat PDPN (gPDPN) has not been established yet. PDPN has been utilized as a lymphatic endothelial cell marker especially in pathological diagnoses; therefore, mAbs for immunohistochemical analyses using formalin-fixed paraffin-embedded tissues are needed. Although we recently demonstrated that an anti-bovine PDPN mAb, PMab-44 cross-reacted with gPDPN, PMab-44 did not detect lymphatic endothelial cells in immunohistochemistry. In this study, we immunized mice with gPDPN-overexpressing Chinese hamster ovary (CHO)-K1 (CHO/gPDPN) cells, and screened mAbs against gPDPN using flow cytometry. One of the mAbs, PMab-235 (IgG

Identifiants

pubmed: 31338471
doi: 10.1016/j.heliyon.2019.e02063
pii: S2405-8440(19)35723-8
pii: e02063
pmc: PMC6626078
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e02063

Références

J Biol Chem. 2003 Dec 19;278(51):51599-605
pubmed: 14522983
Oncogene. 2004 Nov 4;23(52):8552-6
pubmed: 15361850
Tumour Biol. 2005 Jul-Aug;26(4):195-200
pubmed: 16006773
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1301-7
pubmed: 16979138
FEBS Lett. 2007 Jan 23;581(2):331-6
pubmed: 17222411
Am J Pathol. 2007 Apr;170(4):1337-47
pubmed: 17392172
J Biol Chem. 2007 Sep 7;282(36):25993-6001
pubmed: 17616532
Blood. 2010 Jul 29;116(4):661-70
pubmed: 20363774
Pathol Int. 2010 Mar;60(3):193-202
pubmed: 20403045
Acta Histochem Cytochem. 2012 Aug 30;45(4):227-37
pubmed: 23012488
Clin Exp Metastasis. 2013 Apr;30(4):441-6
pubmed: 23161183
Am J Vet Res. 1990 Jul;51(7):1139-43
pubmed: 2389892
Sci Rep. 2014 Aug 01;4:5924
pubmed: 25080943
Oncotarget. 2015 Apr 20;6(11):9045-60
pubmed: 25826087
Monoclon Antib Immunodiagn Immunother. 2015 Jun;34(3):154-61
pubmed: 26090592
Monoclon Antib Immunodiagn Immunother. 2015 Dec;34(6):396-403
pubmed: 26683179
Monoclon Antib Immunodiagn Immunother. 2016 Feb;35(1):41-7
pubmed: 26788987
PLoS One. 2016 Mar 31;11(3):e0152912
pubmed: 27031228
Monoclon Antib Immunodiagn Immunother. 2016 Jun 7;35(4):186-190
pubmed: 27267652
Cancer Sci. 2016 Sep;107(9):1198-205
pubmed: 27294401
Monoclon Antib Immunodiagn Immunother. 2016 Aug;35(4):212-6
pubmed: 27380308
Monoclon Antib Immunodiagn Immunother. 2016 Oct;35(5):263-266
pubmed: 27788030
Monoclon Antib Immunodiagn Immunother. 2016 Dec;35(6):293-299
pubmed: 27801621
Monoclon Antib Immunodiagn Immunother. 2016 Dec;35(6):304-306
pubmed: 27918691
Monoclon Antib Immunodiagn Immunother. 2017 Apr;36(2):72-76
pubmed: 28387591
Monoclon Antib Immunodiagn Immunother. 2017 Jun;36(3):104-112
pubmed: 28504613
Sci Rep. 2017 Jul 17;7(1):5577
pubmed: 28717161
Monoclon Antib Immunodiagn Immunother. 2017 Oct;36(5):224-230
pubmed: 28737447
Oral Oncol. 2018 Mar;78:126-136
pubmed: 29496040
Monoclon Antib Immunodiagn Immunother. 2018 Nov;37(5):233-237
pubmed: 30362932
Monoclon Antib Immunodiagn Immunother. 2019 Apr;38(2):96-99
pubmed: 30457925
Monoclon Antib Immunodiagn Immunother. 2018 Dec;37(6):265-268
pubmed: 30570359
Monoclon Antib Immunodiagn Immunother. 2018 Dec;37(6):272-274
pubmed: 30592702
Monoclon Antib Immunodiagn Immunother. 2019 Feb;38(1):30-36
pubmed: 30681406
Monoclon Antib Immunodiagn Immunother. 2019 Feb;38(1):18-24
pubmed: 30802179
Biochem Biophys Rep. 2019 Apr 01;18:100631
pubmed: 30984883
Biochem Biophys Rep. 2019 Apr 05;18:100633
pubmed: 30997422
Monoclon Antib Immunodiagn Immunother. 2019 Apr;38(2):89-95
pubmed: 31009336
Biochem Biophys Rep. 2019 Apr 28;18:100644
pubmed: 31061899
Lymphology. 1979 Mar;12(1):14-7
pubmed: 449395

Auteurs

Yoshikazu Furusawa (Y)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
New Industry Creation Hatchery Center, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
ZENOAQ RESOURCE CO., LTD., 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, Fukushima, 963-0196, Japan.

Shinji Yamada (S)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Takuro Nakamura (T)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Masato Sano (M)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Yusuke Sayama (Y)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Shunsuke Itai (S)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Junko Takei (J)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Hiroyuki Harada (H)

Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Masato Fukui (M)

ZENOAQ RESOURCE CO., LTD., 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, Fukushima, 963-0196, Japan.

Mika K Kaneko (MK)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Yukinari Kato (Y)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
New Industry Creation Hatchery Center, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Classifications MeSH